PEP/NEWS — Peptide intel. Daily.

Use Code THOMAS25 for 25% off Your First Order of SEED: http://seed.com/thomasyt This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like this that we are able to provide the

In this Huberman Lab Essentials episode, my guest is Dr. Sam Harris, PhD, a neuroscientist, bestselling author, and world-renowned meditation teacher whose work focuses on consciousness, ethics, and religion. We discuss how meditation can h

A new study found that planned, structured exercise — not just general daily movement — protects against specific molecular markers of muscle aging. The distinction matters for anyone designing a training protocol aimed at longevity.

Researchers targeted GPR40, a receptor in thymic epithelial cells, to slow the thymus from shrinking with age. The thymus is central to immune function, and its decline is a key driver of immunosenescence. The finding was published in Aging Cell.

A team used exosomes from mesenchymal stem cells to counter harmful metabolic changes in mouse livers. Exosome-based therapies are gaining traction as a delivery mechanism. This adds to a growing body of preclinical evidence for the approach.

Attia reviews the latest data on GLP-1 receptor agonists (a class of metabolic peptides including semaglutide and tirzepatide) and lean mass loss. His key finding: patients who hit protein targets and do resistance training lose very little muscle. The evidence base for that claim is now stronger.

Arrowhead's plozasiran cut triglyceride levels and reduced pancreatitis cases in its latest trial. Analysts called the safety and efficacy profile best-case. The drug now looks competitive with rival Ionis treatments in this metabolic space.

New research from Immorta Bio found that pairing a senolytic vaccine (which clears aged, dysfunctional cells) with mesenchymal stem cells produced a stronger effect than either alone. The caveat: results come from acute, artificially induced injury models, not natural aging.

The FDA approved GSK's new ROS1-targeting lung cancer medicine under accelerated review. It's GSK's first oncology drug in this indication and follows its acquisition of Nuvalent. The approval validates the company's multi-billion-dollar push into targeted cancer therapy.

A new study suggests that aging and certain Parkinson's-linked mutations first create inflammation in peripheral tissues. Extracellular vesicles then carry that inflammatory signal to the brain. If confirmed, this would shift where interventions should target.

Nature Aging researchers found that blocking a specific molecular axis — CDK4/6–RARα–NF-κB — cuts senescence-driven inflammation and improves tissue function in aging and post-chemotherapy models. The NF-κB pathway (a key inflammation switch) is already a peptide research target.

Nature Aging researchers showed that hematopoietic stem cells accumulate epigenetic memory of past immune challenges with age. This trained immunity appears to drive the chronic low-grade inflammation seen in older adults.